SELLAS Reports Positive Phase 3 Results for AML Vaccine, Plans FDA Discussions in 2027
Key Points
- SELLAS' Phase 3 REGAL trial met its primary endpoint, with galinpepimut-S showing a 41% reduction in the risk of death in AML, median overall survival of 24.0 months versus 14.7 months for best available treatment.
- GPS was generally well tolerated as maintenance therapy for AML patients in second or subsequent remission who were not eligible for stem cell transplantation, with mainly mild to moderate adverse events.
- SELLAS plans FDA discussions on the data and is preparing a Biologics License Application submission in the first half of 2027.
SELLAS Life Sciences Group has reported positive results from its pivotal Phase 3 REGAL trial, with its investigational cancer vaccine galinpepimut-S (GPS) demonstrating a statistically significant overall survival benefit in patients with acute myeloid leukemia (AML).
The randomized study met its primary endpoint, showing a 41% reduction in the risk of death among patients receiving GPS compared with those assigned to best available treatment (BAT). Median overall survival reached 24.0 months in the GPS group, compared with 14.7 months among patients receiving BAT. The results produced a hazard ratio of 0.59 and a two-sided p-value of 0.035.
The trial evaluated GPS as maintenance monotherapy in patients who had achieved a second or subsequent complete remission, or complete remission with incomplete platelet recovery, following second- or later-line salvage therapy. Participants were not eligible for, or unable to undergo, allogeneic stem cell transplantation.
This patient population represents a significant unmet medical need, as treatment options remain limited for individuals with relapsed AML who achieve another remission but cannot proceed to a donor stem cell transplant.
GPS was generally well tolerated in the study, with no new safety signals identified. Treatment-related adverse events were primarily mild to moderate (Grade 1 or 2), with injection-site reactions among the most commonly reported. The two treatment groups were also balanced for prognostic factors, while the relatively small number of patients who subsequently underwent hematopoietic stem cell transplantation was evenly distributed between the arms.
Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS, says the results represent an important milestone for the company and provide Phase 3 clinical validation of its WT1-targeted immunotherapy platform. He emphasized the potential significance of the survival findings for AML patients who have few remaining treatment options.
Following the topline results, SELLAS plans to meet with the U.S. Food and Drug Administration to discuss the data and potential accelerated filing strategy. The company is preparing for a Biologics License Application (BLA) submission in the first half of 2027.
The primary endpoint analysis was conducted after the trial reached its prespecified threshold of 80 deaths, in accordance with the statistical analysis plan. Additional analyses covering secondary endpoints and other prespecified measures are ongoing. SELLAS plans to present the complete findings at a future major medical conference and submit the results for publication in a peer-reviewed journal.
Members of the REGAL Study Steering Committee said the findings could have implications for maintenance treatment in patients with AML who are unable to undergo transplantation. The committee noted that GPS is designed to stimulate immune responses against residual leukemia cells, potentially helping patients maintain remission for longer periods.
The REGAL study enrolled 126 patients who were randomized equally to receive GPS or investigator-selected BAT. Control treatments included observation, hypomethylating agents, venetoclax and low-dose cytarabine, either individually or in combination.
Galinpepimut-S is an investigational, off-the-shelf immunotherapeutic cancer vaccine designed to stimulate both CD4+ and CD8+ T-cell responses against cells expressing the Wilms’ tumor 1 (WT1) protein. WT1 is found in a range of hematologic malignancies and solid tumors, including AML.
Licensed from Memorial Sloan Kettering Cancer Center, GPS was originally discovered in the laboratory of David A. Scheinberg. The vaccine incorporates four WT1-derived peptides intended to generate an immune response across multiple human leukocyte antigen (HLA) types. Its development strategy focuses on targeting residual cancer cells following remission to potentially extend survival.
SELLAS is also advancing SLS009 (tambiciclib), an investigational CDK9 inhibitor being developed for AML and other cancer indications. The company is a late-stage clinical biopharmaceutical organization focused on developing therapies for a range of malignancies.
Additional information is available at www.sellaslifesciences.com.
Total Page Views: 7

















